TerminatedPhase 1NCT04070781

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

Studying Graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Columbia University
Principal Investigator
Markus Mapara, MD
Columbia University
Intervention
Itacitinib(drug)
Enrollment
1 target
Eligibility
18-99 years · All sexes
Timeline
20202021

Study locations (2)

Collaborators

Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04070781 on ClinicalTrials.gov

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Graft versus host disease

← Back to all trials